These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25877635)

  • 1. Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study).
    Magyari M; Bach Søndergaard H; Sellebjerg F; Soelberg Sørensen P
    Mult Scler Relat Disord; 2013 Apr; 2(2):141-6. PubMed ID: 25877635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.
    Sellebjerg F; Krakauer M; Hesse D; Ryder LP; Alsing I; Jensen PE; Koch-Henriksen N; Svejgaard A; Soelberg Sørensen P
    Eur J Neurol; 2009 Dec; 16(12):1291-8. PubMed ID: 19558503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice.
    van der Voort LF; Kok A; Visser A; Oudejans CB; Caldano M; Gilli F; Bertolotto A; Polman CH; Killestein J
    Mult Scler; 2009 Feb; 15(2):212-8. PubMed ID: 18805837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
    Hesse D; Sellebjerg F; Sorensen PS
    Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
    Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon-β.
    Hesse D; Frederiksen JL; Koch-Henriksen N; Schreiber K; Stenager E; Heltberg A; Ravnborg M; Bendtzen K; Sellebjerg F; Sorensen PS
    Eur J Neurol; 2009 Jan; 16(1):43-7. PubMed ID: 19087149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent.
    Sominanda A; Hillert J; Fogdell-Hahn A
    J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):57-62. PubMed ID: 17911184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    Sorensen PS; Koch-Henriksen N; Bendtzen K
    Mult Scler; 2007 Jun; 13(5):616-21. PubMed ID: 17548440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
    Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
    Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
    Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
    Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
    Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
    Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
    Polman CH; Bertolotto A; Deisenhammer F; Giovannoni G; Hartung HP; Hemmer B; Killestein J; McFarland HF; Oger J; Pachner AR; Petkau J; Reder AT; Reingold SC; Schellekens H; Sørensen PS
    Lancet Neurol; 2010 Jul; 9(7):740-50. PubMed ID: 20610349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point.
    Hermanrud C; Ryner ML; Engdahl E; Fogdell-Hahn A
    J Interferon Cytokine Res; 2014 Jul; 34(7):498-504. PubMed ID: 24444338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
    Malucchi S; Capobianco M; Gilli F; Marnetto F; Caldano M; Sala A; Bertolotto A
    Neurol Sci; 2005 Dec; 26 Suppl 4():S213-4. PubMed ID: 16388361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimising MS disease-modifying therapies: antibodies in perspective.
    Giovannoni G
    J Neurol; 2004 Sep; 251 Suppl 5():v30-v35. PubMed ID: 15549353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should we measure the bioavailability of interferon beta in vivo in patients with multiple sclerosis?
    Hemmer B; Berthele A
    Nat Clin Pract Neurol; 2009 Mar; 5(3):126-7. PubMed ID: 19262585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.
    Garcia-Montojo M; Dominguez-Mozo MI; de las Heras V; Bartolome M; Garcia-Martinez A; Arroyo R; Alvarez-Lafuente R
    Eur J Neurol; 2010 Mar; 17(3):470-8. PubMed ID: 20050906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.
    Bertolotto A; Sala A; Malucchi S; Marnetto F; Caldano M; Di Sapio A; Capobianco M; Gilli F
    J Neurol Neurosurg Psychiatry; 2004 Sep; 75(9):1294-9. PubMed ID: 15314118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.